369 related articles for article (PubMed ID: 23630412)
1. Phentermine and topiramate for the management of obesity: a review.
Cosentino G; Conrad AO; Uwaifo GI
Drug Des Devel Ther; 2013; 7():267-78. PubMed ID: 23630412
[TBL] [Abstract][Full Text] [Related]
2. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
Kiortsis DN
Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
[TBL] [Abstract][Full Text] [Related]
3. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
4. Combination phentermine and topiramate extended release in the management of obesity.
Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
[TBL] [Abstract][Full Text] [Related]
5. Phentermine and topiramate extended release (Qsymia™): first global approval.
Cameron F; Whiteside G; McKeage K
Drugs; 2012 Oct; 72(15):2033-42. PubMed ID: 23039320
[TBL] [Abstract][Full Text] [Related]
6. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
[TBL] [Abstract][Full Text] [Related]
7. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.
Garvey WT
Expert Opin Drug Saf; 2013 Sep; 12(5):741-56. PubMed ID: 23738843
[TBL] [Abstract][Full Text] [Related]
8. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
9. Phentermine and topiramate extended-release for the obesity: new kids on the block.
Katsi V; Marketou M; Kallistratos MS; Tousoulis D; Makris T; Manolis AJ; Vardas P; Kallikazaros I
Recent Pat Cardiovasc Drug Discov; 2013 Apr; 8(1):35-41. PubMed ID: 23565717
[TBL] [Abstract][Full Text] [Related]
10. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
Bays HE; Gadde KM
Drugs Today (Barc); 2011 Dec; 47(12):903-14. PubMed ID: 22348915
[TBL] [Abstract][Full Text] [Related]
11. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Halpern B; Mancini MC
Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
Winslow DH; Bowden CH; DiDonato KP; McCullough PA
Sleep; 2012 Nov; 35(11):1529-39. PubMed ID: 23115402
[TBL] [Abstract][Full Text] [Related]
13. Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
Halpern B; Faria AM; Halpern A
Expert Rev Clin Pharmacol; 2013 May; 6(3):235-41. PubMed ID: 23656337
[TBL] [Abstract][Full Text] [Related]
14. New obesity agents: lorcaserin and phentermine/topiramate.
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
Jordan J; Astrup A; Engeli S; Narkiewicz K; Day WW; Finer N
J Hypertens; 2014 Jun; 32(6):1178-88. PubMed ID: 24621808
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
Aronne LJ; Wadden TA; Peterson C; Winslow D; Odeh S; Gadde KM
Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
[TBL] [Abstract][Full Text] [Related]
18. New pharmacological treatments for the management of obesity.
Hurt RT; Edakkanambeth Varayil J; Ebbert JO
Curr Gastroenterol Rep; 2014; 16(6):394. PubMed ID: 24828101
[TBL] [Abstract][Full Text] [Related]
19. Obesity Pharmacotherapy.
Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
[TBL] [Abstract][Full Text] [Related]
20. Combination phentermine and topiramate for weight maintenance: the first Australian experience.
Neoh SL; Sumithran P; Haywood CJ; Houlihan CA; Lee FT; Proietto J
Med J Aust; 2014 Aug; 201(4):224-6. PubMed ID: 25164851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
